Sonnet BioTherapeutics, Roche collaborate for SON-1010 with atezolizumab

Sonnet BioTherapeutics Holdings announced a clinical collaboration agreement with Roche. A clinical trial will be conducted to assess the safety and preliminary efficacy of SON-1010 in combination with Roche’s atezolizumab in patients with platinum-resistant ovarian cancer. Interleukin-12 is a cytokine, or an immune cell-signaling protein, that enhances the activity of natural killer cells and T cells. SON-1010 is a proprietary version of native human IL-12, configured using Sonnet’s fully human albumin binding platform, which targets the tumor microenvironment and extends the pharmacokinetics (PK) and subsequent pharmacodynamics of the molecule. Atezolizumab is an immune checkpoint inhibitor approved for the treatment of some of the most aggressive and difficult-to-treat forms of cancer. The characteristics of ovarian cancer present a unique opportunity to assess the combination of these two agents in an indication that persists as a large unmet medical need. Sonnet and Roche have entered into a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer patient setting. Further, the companies would provide SON-1010 and atezolizumab, respectively, for use in the Phase 1b/Phase 2a safety and efficacy study.